Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases. AMPPLIFY particles are selectively-... Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases. AMPPLIFY particles are selectively-sized nanoparticles and have proprietary coatings. It has applied the AMPPLIFY technology to create nanosuspensions of loteprednol etabonate, or LE, acorticosteroid designed for ocular applications, resulting in two product candidates. INVELTYS was approved in August 2018 for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25 per cent is in Phase 3 development for the temporary relief of the signs and symptoms of dry eye disease. 詳細を表示
ARLINGTON, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
ARLINGTON, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.54 | 7.55244755245 | 7.15 | 7.85 | 6.955 | 59914 | 7.63052371 | CS |
4 | 1.36 | 21.4849921011 | 6.33 | 8.79 | 6.2401 | 55608 | 7.43857236 | CS |
12 | 0.76 | 10.9668109668 | 6.93 | 8.79 | 5.67 | 37086 | 7.07350572 | CS |
26 | 0.77 | 11.1271676301 | 6.92 | 8.79 | 4.95 | 25532 | 6.73236156 | CS |
52 | 0.58 | 8.15752461322 | 7.11 | 8.79 | 4.21 | 77468 | 6.61712551 | CS |
156 | -31.335 | -80.2946828956 | 39.025 | 97 | 3.5444 | 710840 | 29.96236049 | CS |
260 | -324.81 | -97.6872180451 | 332.5 | 734 | 3.5444 | 1056445 | 207.0281194 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約